Specific Aims

On August 2, 2026, every hospital in Europe deploying clinical AI will face fines of up to 3% of global annual turnover for high-risk AI non-compliance under the EU AI Act (EU 2024/1689) Art. 99(4) [X-38] [X-51], and not one can currently prove compliance. Five overlapping regulatory frameworks govern EU health data (GDPR, EU AI Act [X-38], EHDS [X-52], NIS2, MDR), combined maximum penalty exposure reaches 11% of annual revenue (GDPR 4% + AI Act 3% high-risk + NIS2 2% + MDR 2%), and no architecture validates compliance across all five simultaneously. GDPR enforcement has produced €22.8M in healthcare fines across 237 actions [X-50] (CMS Tracker, 2025). The EHDS (EU 2025/327) [X-52] mandates Health Data Access Bodies under Art. 37 but provides no governance framework for those bodies to implement. Analysis of 15 EU/UK violations reveals that the majority fail in the same three dimensions: community accountability, operational practice, and institutional learning [I-21] [W-10] (Hadley, 2026), a pattern identical to US failures we have already addressed [I-24] [W-6]. The gap is the absence of a validated framework for simultaneous multi-regulatory compliance in European healthcare, without which the EHDS cannot deliver on its mandate for digitalisation and data exchange (IHI SO4) [X-59].

The long-term goal is to establish a mathematically validated governance framework for the EHDS [X-52], replicable across 27 member states by 2031. The objective is to fill the gap above by deploying the CANONIC MAGIC 255 framework at two HDAB pilot sites and one cross-border oncology corridor, producing an open compliance model for pan-European adoption. Our central hypothesis is that an eight-dimensional governance framework that augments existing health information systems can achieve constructive mathematical proof of simultaneous compliance with all five EU frameworks, both within institutions and across member state boundaries. This hypothesis has been formulated on the basis of: (1) MammoChat (mammochat.ai), a governed clinical AI supported by AdventHealth (51 hospitals, letter of support) [I-12], with two registered clinical trials (NCT06604078 [I-13], 199 patients enrolled; NCT07214883 [I-39], recruiting toward 20,000 patients, UCF administration), funded by a $2M Casey DeSantis Florida Cancer Innovation Award (UCF) [I-16]; (2) CaribChat (caribchat.ai) [I-38], live in Trinidad with real oncology patients ledgered through the Caribbean Association of Oncology and Hematology [X-93] — where the EU has five overlapping regulations and no compliance architecture, the Caribbean has zero health data legislation [X-86] and relies entirely on institutional ethics boards, yet MAGIC 255 governs both extremes because the proof is mathematical, not jurisdictional; and (3) six patent families (90 claims, 252 prior art searches, zero blockers [I-40] [I-43]), $38M+ in prior PI funding [I-1] [I-18] [I-19] [I-20] (Hadley; 67 peer-reviewed publications [P-1]–[P-68], h-index 31). Critically, neither MammoChat nor CaribChat is a compliance checklist or database. Both are fully governed operating surfaces where AI enforces governance at every interaction: every patient conversation is append-only ledgered, every clinical claim is evidence-traced to its source, and every community learning session is scored across all eight dimensions in real time, making the compliance proof constructive and continuous rather than declarative and retrospective. The rationale is that, once validated against the EU stack, the compliance pathway every European health system will need by August 2026 [X-51] will exist for the first time.

Aim 1: Establish that EU governance failures share a common dimensional architecture amenable to systematic remediation (WP2, €800K). Lead: DHIR Malta (Calleja); policy: Douas Maadi (EC Evaluator, UC3M). Working hypothesis: EU violations share the deficit pattern documented in US [I-24] [W-6] and Caribbean [X-86] failures. Aim 2: Determine whether MAGIC 255, validated in US and Caribbean contexts, achieves constructive compliance proof under the EU regulatory stack (WP3+WP4, €3.5M). Lead: OncoNex.eu [I-23] and University of Malta; Pilot Site 2: AtG Therapeutics, Barcelona (Ouahid Benkaddour). Working hypothesis: The framework will achieve score 255 at DHIR Malta and a Spanish oncology centre. Aim 3: Determine whether cross-border governance maintains provable compliance across member state boundaries (WP5, €2.5M). Lead: Excellenting [I-22] (Douas Maadi, Ouahid Benkaddour); corridor: Barcelona ↔ Malta ↔ Madrid. Working hypothesis: The corridor will achieve corridor-level 255 despite differing GDPR implementations.

Expected outcomes. Aim 1: dimensional deficit map for 10 member states with HDAB governance specification. Aim 2: two HDAB integrations with validated MAGIC 255 scores — first constructive proof of EU regulatory compliance. Aim 3: first cross-border health data governance deployment under EHDS. These outcomes close the €344B governance gap [I-21] [W-10], delivering the digitalisation and data exchange infrastructure IHI SO4 [X-59] requires at 80:1 cost ratio, with a replicable model for 27 member states before 2031.

References

References will expand as the Research Strategy is drafted.